Literature DB >> 33917013

Immunomodulatory Effect of Microglia-Released Cytokines in Gliomas.

Marika Lanza1, Giovanna Casili1, Michela Campolo1, Irene Paterniti1, Cristina Colarossi2, Marzia Mare2, Raffella Giuffrida3, Maria Caffo4, Emanuela Esposito1, Salvatore Cuzzocrea1.   

Abstract

Microglia, a type of differentiated tissue macrophage, are considered to be the most plastic cell population of the central nervous system (CNS). Microglia substantially contribute to the growth and invasion of tumor mass in brain tumors including glioblastoma (GB). In response to pathological conditions, resting microglia undergo a stereotypic activation process and become capable of phagocytosis, antigen presentation, and lymphocyte activation. Considering their immune effector function, it is not surprising to see microglia accumulation in almost every CNS disease process, including malignant brain tumors. Large numbers of glioma associated microglia and macrophages (GAMs) can accumulate within the tumor where they appear to have an important role in prognosis. GAMs constitute the largest portion of tumor infiltrating cells, contributing up to 30% of the entire glioma mass and upon interaction with neoplastic cells. GAMs acquire a unique phenotype of activation, including both M1 and M2 specific markers. It has been demonstrated that microglia possess a dual role: on one hand, microglia may represent a CNS anti-tumor response, which is inactivated by local secretion of immunosuppressive factors by glioma cells. On the other hand, taking into account that microglia are capable of secreting a variety of immunomodulatory cytokines, it is possible that they are attracted by gliomas to promote tumor growth. A better understanding of microglia-glioma interaction will be helpful in designing novel immune-based therapies against these fatal tumors. Concluding, as microglia significantly may contribute to glioma biology, favoring tumor growth and invasiveness, these cells represent a valuable alternative/additional target for the development of more effective treatments for gliomas.

Entities:  

Keywords:  brain tumors; immunotherapy; microglia

Year:  2021        PMID: 33917013     DOI: 10.3390/brainsci11040466

Source DB:  PubMed          Journal:  Brain Sci        ISSN: 2076-3425


  8 in total

1.  Thioredoxin Reductase Inhibitors as Potential Antitumors: Mercury Compounds Efficacy in Glioma Cells.

Authors:  Vanessa Pires; Isabella Bramatti; Michael Aschner; Vasco Branco; Cristina Carvalho
Journal:  Front Mol Biosci       Date:  2022-06-23

Review 2.  Current Understanding of Exosomal MicroRNAs in Glioma Immune Regulation and Therapeutic Responses.

Authors:  Jinwu Peng; Qiuju Liang; Zhijie Xu; Yuan Cai; Bi Peng; Jianbo Li; Wenqin Zhang; Fanhua Kang; Qianhui Hong; Yuanliang Yan; Mingyu Zhang
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

Review 3.  COVID-19-Induced Stroke and the Potential of Using Mesenchymal Stem Cells-Derived Extracellular Vesicles in the Regulation of Neuroinflammation.

Authors:  Leyla Norouzi-Barough; Amir Asgari Khosroshahi; Ali Gorji; Fariba Zafari; Mohammad Shahverdi Shahraki; Sadegh Shirian
Journal:  Cell Mol Neurobiol       Date:  2022-01-13       Impact factor: 5.046

4.  Immunomodulatory and Antiprotozoal Potential of Fabricated Sesamum radiatum Oil/Polyvinylpyrrolidone/Au Polymeric Bionanocomposite Film.

Authors:  Nawal A Alarfaj; Musarat Amina; Nawal M Al Musayeib; Maha F El-Tohamy; Gadah A Al-Hamoud
Journal:  Polymers (Basel)       Date:  2021-12-10       Impact factor: 4.329

5.  Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM.

Authors:  Bao Liu; Qifeng Ji; Ying Cheng; Miao Liu; Bangle Zhang; Qibing Mei; Daozhou Liu; Siyuan Zhou
Journal:  J Nanobiotechnology       Date:  2022-03-27       Impact factor: 10.435

6.  The Dynamics of Tumor-Infiltrating Myeloid Cell Activation and the Cytokine Expression Profile in a Glioma Resection Site during the Post-Surgical Period in Mice.

Authors:  Jescelica Ortiz-Rivera; Alejandro Albors; Yuriy Kucheryavykh; Jeffrey K Harrison; Lilia Kucheryavykh
Journal:  Brain Sci       Date:  2022-07-07

7.  Fas/FasL Contributes to HSV-1 Brain Infection and Neuroinflammation.

Authors:  Malgorzata Krzyzowska; Andrzej Kowalczyk; Katarzyna Skulska; Karolina Thörn; Kristina Eriksson
Journal:  Front Immunol       Date:  2021-08-30       Impact factor: 7.561

Review 8.  The Use of Iron Oxide Nanoparticles to Reprogram Macrophage Responses and the Immunological Tumor Microenvironment.

Authors:  Vladimir Mulens-Arias; José Manuel Rojas; Domingo F Barber
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.